ArticleRMD open2026
Renal involvement in ankylosing spondylitis: a retrospective, population-based cohort study using data from the TriNetX Global Network.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal involvement in ankylosing spondylitis (AS) is recognised but understudied, with heterogeneous reports ranging from urinalysis abnormalities to end-stage disease and malignancy. Robust, contemporary and population-level estimates remain lacking.
objectiveTo quantify the burden and risk of major nephrological outcomes in AS versus matched controls, estimate long-term occurrence, and explore sex-specific differences.
methodsWe performed a retrospective, population-based cohort study using the TriNetX Global Collaborative Network of anonymised electronic health records. Adults with AS were compared 1:1 with controls using propensity score matching across demographic factors and relevant comorbidities. The primary renal outcome was chronic kidney disease (CKD), while the secondary outcomes were as follows: acute kidney injury (AKI), dialysis initiation, glomerular diseases, tubulointerstitial nephropathies, proteinuria, haematuria, urolithiasis, nephrological neoplasms and kidney transplantation. Time-to-event analyses used Cox models; robustness was assessed in prespecified sensitivity analyses.
resultsAfter matching, AS was associated with markedly higher hazards across the full spectrum of renal outcomes. The risk of developing CKD (primary outcome) was more than twofold higher in the AS cohort (HR 2.51; 95% CI 2.21 to 2.84). Among secondary outcomes, the highest risk was observed for dialysis initiation (HR 7.58; 95% CI 6.19 to 9.27), followed by AKI (HR 2.18; 95% CI 2.03 to 2.35) and glomerular diseases (HR 2.06; 95% CI 1.71 to 2.49). Associations were consistent across prespecified sensitivity analyses.
conclusionsAS confers a broad, multifactorial increase in renal morbidity. These findings support routine nephrological surveillance within rheumatology pathways. A multidisciplinary approach is warranted to enable earlier detection and mitigate irreversible kidney injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.